Tvardi Therapeutics is developing drugs targeting STAT3 for Idiopathic Pulmonary Fibrosis and HCC, and received FDA orphan drug designation for the HCC indication.
2 reports, 2 independent
Updated Jul 7
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tvardi Therapeutics is developing drugs targeting STAT3 for Idiopathic Pulmonary Fibrosis and HCC, and received FDA orphan drug designation for the HCC indication.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- manilatimes.net
- BarchartThis ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built around early